Fundamentals of US Oncology Pricing: The Art and the Science

Megan Lambert, Filiz Yucebay

Key considerations for developing U.S. pricing strategies for innovative oncology therapies.

While not a new subject, the rising cost of cancer care is leading to increased emphasis on value-based care and heightened scrutiny of oncology launch pricing. Therefore, a broad, multistakeholder perspective is required to inform a manufacturer’s launch price and corresponding rationale. In addition, activities related to preparing the market, communicating the value proposition and optimizing access must align to best position a product for success.

During this webinar, our hosts — Megan Lambert, Nicholas Economides and Don Creighton (Huron’s life sciences business), as well as clinical pharmacist Filiz Yucebay (Huron’s healthcare business and provider implementation solutions) outlined their key considerations for developing U.S. pricing strategies for innovative oncology therapies and discussed its perspective on the topics above based on their 40 years of combined experience in pricing, across both industry and consulting.

Contact Us

We use cookies on our website to provide you with a more personalized digital experience, enable website functionality and understand the performance of our site. You may review our Privacy Statement and our Cookies Policy. By using this site you agree to our use of cookies. I Accept

;